Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine.</li>
<li>Industrial, healthcare and consumer discretionary led the inflow while financials led the outflow.</li>
<li>We highlight inflows into Shenzhen Inovance and Nari Technology that worth investor attention. </li>
</ul>


We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine.
Industrial, healthcare and consumer discretionary led the inflow while financials led the outflow.
We highlight inflows into Shenzhen Inovance and Nari Technology that worth investor attention. 


Northbound Flows: Shenzhen Inovance, Nari Technology

<ul>
<li>We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine.</li>
<li>Information Technology, Materials, and Real Estate led the inflows while Health Care and Communication Services led the outflows.</li>
<li>We highlight inflows into Moutai, CSCC, Beijing Oriental Yuhong, Sungrow and outflows from Jiangsu Hengrui.</li>
</ul>


We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine.
Information Technology, Materials, and Real Estate led the inflows while Health Care and Communication Services led the outflows.
We highlight inflows into Moutai, CSCC, Beijing Oriental Yuhong, Sungrow and outflows from Jiangsu Hengrui.


Northbound Flows: Moutai, CSCC, Beijing Oriental Yuhong, Sungrow

<ul>
<li>We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine.</li>
<li>Consumer discretionary, information technology and healthcare led the outflows of USD 969 million last week.</li>
<li>We highlight inflows into Sungrow Power and outflows from Jiangsu Hengrui, Ganfeng Lithium, and Cosco Shipping.</li>
</ul>


We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine.
Consumer discretionary, information technology and healthcare led the outflows of USD 969 million last week.
We highlight inflows into Sungrow Power and outflows from Jiangsu Hengrui, Ganfeng Lithium, and Cosco Shipping.


Northbound Flows: Sungrow Power, Hengrui, Ganfeng, Cosco Shipping

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Shanghai Junshi Biosciences  / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-junshi-bioscience-h" target="_blank" data-smartkarma-citation="entities:27760:1" rel="noopener">Shanghai Junshi Bioscience Co. Ltd. (1877 HK)'s</a> oncology drug candidate toripalimab marketing application is currently under priority review by the FDA, with a target action date of April 30, 2022.</li>
<li>However, FDA may reject toripalimab application, as it is predominantly based on China clinical trial data. Toripalimab may also face delay in FDA decision due to delayed regulatory inspection.</li>
<li>PD-1 drug market in the U.S. is intensely competitive, making the commercialization prospect of a new drug quite difficult. Toripalimab reported muted performance in China due to pricing headwind.</li>
</ul>



Shanghai Junshi Bioscience Co. Ltd. (1877 HK)'s oncology drug candidate toripalimab marketing application is currently under priority review by the FDA, with a target action date of April 30, 2022.
However, FDA may reject toripalimab application, as it is predominantly based on China clinical trial data. Toripalimab may also face delay in FDA decision due to delayed regulatory inspection.
PD-1 drug market in the U.S. is intensely competitive, making the commercialization prospect of a new drug quite difficult. Toripalimab reported muted performance in China due to pricing headwind.


Shanghai Junshi Bioscience (1877 HK): Uncertainties Prevailing Ahead of First U.S. Drug Approval

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

CSPC Pharmaceutical Group / Equity Bottom-Up

<ul>
<li>Due to the lack of differentiated and frontier enough target layout, the commercialization potential would be more easily questioned, with high uncertainty of having the next NBP level products.</li>
<li>CSPC has made easy money from a few large varieties/generic drugs for many years, but is destined to make the business transformation more difficult, because the “opportunity cost” is high.</li>
<li>CSPC's products have lost their pricing power. Therefore, when its valuation is very low or the entire sector is moving upward, this stock could be traded due to positive momentum.</li>
</ul>


Due to the lack of differentiated and frontier enough target layout, the commercialization potential would be more easily questioned, with high uncertainty of having the next NBP level products.
CSPC has made easy money from a few large varieties/generic drugs for many years, but is destined to make the business transformation more difficult, because the “opportunity cost” is high.
CSPC's products have lost their pricing power. Therefore, when its valuation is very low or the entire sector is moving upward, this stock could be traded due to positive momentum.


CSPC Pharmaceutical Group (1093.HK) - Conservative About the Business Transformation Outlook

China

Jiangsu Hengrui Medicine Co., Ltd. develops, manufactures, and markets a variety of medicines and medicine packing materials. The Company's products include anti-tumor medicines, pain-killers, anti-infection medicines, aluminum foil, and other related products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jiangsu Hengrui Medicine (600276 CH)

Northbound Flows: Shenzhen Inovance, Nari Technology

We highlight weekly Hong Kong Connect northbound inflows into Moutai, Yunnan Baiyao, Media Group, Shenzhen Inovance and Nari Technology.

Ke Yan, CFA, FRM

Northbound Flows: Moutai, CSCC, Beijing Oriental Yuhong, Sungrow

We highlight weekly northbound inflows into Moutai, CSCC, Beijing Oriental Yuhong, Sungrow as well as outflows from Jiangsu Hengrui.

Ke Yan, CFA, FRM

Northbound Flows: Sungrow Power, Hengrui, Ganfeng, Cosco Shipping

We highlight HK Connect northbound inflows into Sungrow Power and outflows from Jiangsu Hengrui, Ganfeng Lithium, and Cosco Shipping this week.

Ke Yan, CFA, FRM

Shanghai Junshi Bioscience (1877 HK): Uncertainties Prevailing Ahead of First U.S. Drug Approval

Going by the FDA’s recent action, Junshi Bioscience’s toripalimab has a chance to get rejected by the FDA. It may miss the approval timeline....

Tina Banerjee

CSPC Pharmaceutical Group (1093.HK) - Conservative About the Business Transformation Outlook

With unproven R&D capabilities, expired patent and negative policy, it's hard for CSPC to achieve successful transformation, or sacrifice immediate...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)